article thumbnail

Biocon buys Viatris biosimilars for $3.3bn, eyes IPO

pharmaphorum

Biocon has an option on that product until 2025. It will have time to adjust however, as the deal will see Viatris “provide commercial and other transition services for an expected period of two years to ensure continuity of customer service and a smooth transition.” billion.

article thumbnail

Pharmacy Profit: 5 Steps For Ending Strong

DiversifyRx

Let’s break down the exact steps you can take to ensure your year ends on a high note and your pharmacy is ready to thrive in 2025. Optimize Your Tax Situation: Talk to your accountant about potential end-of-year tax strategies, like prepaying expenses for 2025 or making investments in new equipment that can be depreciated.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Customer Relationship Management in Healthcare Industry: Features, Benefits, and Specifics

Viseven

billion by 2025 , with a compound annual growth rate (CAGR) growth of more than 9%. It will enable healthcare providers and junior medical officers to collaborate effectively on specific patients using electronic health records, developing better customer service and increasing customer satisfaction and retention.

article thumbnail

Creative Biolabs Continues Partnering with Pharmaceutical Corporations to Drive Biopharmaceutical Innovation for 2025 and Beyond

Pharma Mirror

As a provider of custom services, Creative Biolabs aims to support the entire process of drug discovery and development for the global pharmaceutical industry using its cutting-edge technology and wide-ranging experiences.